Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04901936Phase 2Recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Dec 2028
- Modality
- PEGylated Peptides
- Countries
- 9
01
Overview
A Phase 2 trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Started Feb 2021; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04901936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901936.